Updated: January 19, 2026

Sudo-Tab Shortage: What Providers and Prescribers Need to Know in 2026

Author

Peter Daggett

Summarize with AI

Current Availability Status (2026)
Understanding CMEA Regulations and Their Clinical Impact
Clinical Indications: When to Recommend Sudo-Tab
Contraindications and Precautions to Review Before Prescribing
Dosing Reference for Providers
Clinical Alternatives When Pseudoephedrine Is Not Appropriate
Patient Counseling Points
How medfinder Can Help Your Patients

A clinical guide for providers on pseudoephedrine (Sudo-Tab) availability in 2026, including CMEA implications, prescription strategies, patient counseling, and alternative therapies.

Clinicians prescribing or recommending Sudo-Tab (pseudoephedrine) should be aware of the unique regulatory landscape surrounding this medication. Unlike most drugs, pseudoephedrine is not in a clinical shortage — but it is subject to federal purchase restrictions that affect patient access in ways that traditional shortage guidance does not address.

This guide provides up-to-date information on pseudoephedrine availability, the regulatory context that shapes patient experience, and clinical strategies to help your patients access this medication effectively.

Current Availability Status (2026)

As of 2026, pseudoephedrine is not listed on the FDA Drug Shortage Database or the ASHP shortage list. The drug is available from multiple generic manufacturers and the pharmaceutical supply chain is stable. However, patients commonly report difficulty obtaining pseudoephedrine due to the requirements imposed by the Combat Methamphetamine Epidemic Act of 2005 (CMEA).

Understanding CMEA Regulations and Their Clinical Impact

The CMEA, enacted in 2006, classified pseudoephedrine as a "scheduled listed chemical product" due to its role as a methamphetamine precursor. Key provisions include:

All pseudoephedrine products must be stored behind the pharmacy counter or in a locked cabinet

Purchasers must present a government-issued photo ID and sign a logbook at time of purchase

Daily purchase limit: 3.6 grams of pseudoephedrine base per purchaser, regardless of formulation

30-day purchase limit: 9 grams from in-store purchases; 7.5 grams via mail order

For most acute patients, these limits pose no practical barrier. However, patients with chronic rhinosinusitis who use pseudoephedrine regularly may bump against monthly purchase caps. Prescribing pseudoephedrine rather than recommending OTC purchase can sometimes alleviate logbook requirements, though state laws vary on this point.

Pseudoephedrine is a sympathomimetic amine that acts primarily as an alpha-adrenergic agonist, causing vasoconstriction of nasal mucosal blood vessels. It is indicated for:

Acute nasal congestion from URTI, sinusitis, or allergic rhinitis

Eustachian tube dysfunction and ear congestion

Short-term (up to 7 days) relief from sinus pressure

Off-label: prevention of otitic barotrauma during air travel or diving (120 mg extended-release 30 minutes before departure)

Contraindications and Precautions to Review Before Prescribing

Pseudoephedrine is contraindicated in patients currently taking or recently (within 2 weeks) discontinuing MAO inhibitors. The combination can precipitate hypertensive crisis. Additional precautions apply to patients with:

Uncontrolled hypertension or cardiovascular disease

Hyperthyroidism

Benign prostatic hyperplasia (may worsen urinary retention)

Narrow-angle glaucoma

Severe renal impairment (use with caution; drug excreted renally)

Pregnancy, particularly the first trimester

Dosing Reference for Providers

Immediate-release (30 mg or 60 mg): 60 mg every 4–6 hours in adults and children ≥12; maximum 240 mg/day

Extended-release 120 mg: 120 mg every 12 hours; maximum 240 mg/day

Extended-release 240 mg: 240 mg once daily; maximum 240 mg/day

Children 6–11: 30 mg every 4–6 hours; maximum 120 mg/day

Half-life is approximately 9–16 hours. Advise patients to avoid taking extended-release formulations close to bedtime due to stimulant effects.

Clinical Alternatives When Pseudoephedrine Is Not Appropriate

When pseudoephedrine is contraindicated or refused by the patient:

Intranasal corticosteroids (fluticasone, triamcinolone, mometasone) — first-line for chronic allergic rhinitis

Oxymetazoline nasal spray (Afrin) — fast-acting; limit to ≤3 days to prevent rhinitis medicamentosa

Second-generation antihistamines (cetirizine, loratadine, fexofenadine) — appropriate for allergic etiology

Ipratropium nasal spray — for rhinorrhea-predominant symptoms

Saline nasal irrigation (NeilMed, neti pot) — adjunctive, safe in all patient populations including pregnancy

Patient Counseling Points

When counseling patients on pseudoephedrine, ensure they understand:

They must ask at the pharmacy counter (not the OTC aisle) and show a photo ID

Do not use for more than 7 days without medical evaluation

Avoid caffeine, which compounds cardiovascular side effects

Do not split or crush extended-release tablets

Monitor for palpitations, elevated blood pressure, or insomnia; these warrant discontinuation

How medfinder Can Help Your Patients

For providers whose patients frequently have trouble navigating pseudoephedrine's behind-the-counter purchasing process, medfinder for providers is a resource worth recommending. medfinder calls pharmacies near your patient to confirm which ones have the medication in stock, then texts your patient the results — eliminating the frustrating and time-consuming process of calling multiple pharmacies to find availability.

For more actionable guidance on helping patients find Sudo-Tab, see: How to Help Your Patients Find Sudo-Tab In Stock: A Provider's Guide

Frequently Asked Questions

No. Pseudoephedrine is not listed on the FDA Drug Shortage Database or the ASHP shortage list as of 2026. It is available from multiple manufacturers. Patients struggle to obtain it primarily due to CMEA regulatory requirements (behind-the-counter sale, ID verification, purchase limits) rather than a supply chain failure.

For patients with chronic sinusitis who use pseudoephedrine regularly, writing a prescription may reduce the administrative burden at the pharmacy counter. However, note that some states still apply purchase limits to prescription pseudoephedrine — check your state law. Prescription status also allows insurance reimbursement where applicable.

Key contraindications include: concurrent MAOI use or use within the past 14 days (risk of hypertensive crisis), uncontrolled hypertension, severe coronary artery disease. Use with caution in patients with hyperthyroidism, BPH, narrow-angle glaucoma, diabetes, or renal impairment. Avoid in the first trimester of pregnancy.

For allergic rhinitis: intranasal corticosteroids (fluticasone, mometasone, triamcinolone) are first-line. For acute short-term relief: oxymetazoline nasal spray (≤3 days). For patients with allergy symptoms: second-generation antihistamines (cetirizine, loratadine). Saline irrigation is a safe adjunct for all patient populations.

Yes. Following the FDA advisory committee's September 2023 ruling that oral phenylephrine (Sudafed PE) is not effective as a nasal decongestant, clinical guidance shifted toward pseudoephedrine as the preferred oral option. This has increased demand for pseudoephedrine products, which can contribute to intermittent local stock fluctuations but has not caused a national shortage.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards